ExpressPlus Drug Transporters

Target Drug Transporters Required by FDA and EMA Guidance

Earlier. Quicker. Cheaper.

This NEW express path to understanding the substrate and inhibition liabilities of your drug candidate delivers clarity earlier with optimized first line assays to identify transporter interactions. It’s the best of both worlds with the speed of ExpressPlus™ and the quality of CellPort Technologies®. We utilize the same validated and rugged test systems that are standard for definitive assays in all transporter screening assays. Plus, study designs are optimized for accuracy and throughput using clinically relevant probe substrates.

Early Screening Benefits

Optimization of SAR/PK/PD
Early insights into DDI liability
9 clinically relevant transporters

9 Clinically Relevant Transporters

Intestinal Efflux Transporters	Hepatic Uptake Transporters	Hepatic Efflux Transporter	Renal Uptake Transporters
P-gp BCRP	OATP1B1 OATP1B3 OCT1	BSEP	OAT1 OAT3 OCT2

Which Key Transporters and Why in Early Screening

Transporters	Assessment	Purpose	Application
P-gp BCRP	Substrate and Inhibition	DDI liabilities and rate limiting steps for absorption and disposition	SAR/PK/PD
OATP1B1 OATP1B3	Inhibition	DDI liability (statins)	SAR/PK/PD
BSEP	Inhibition	Hepatotoxicity	SAR/PK/PD
OAT1 OAT3 OCT2	Inhibition	DDI liability (cimetidine, metformin, HIV protese inhibitors)	SAR/PK/PD

	*View all ExpressPlus Transporter Assays*
	Drug Transporter Primer
	Transporter Test System Selection
	Transporter Test Compound Characterization